Severe disease, unaltered leukocyte migration, and reduced IFN-gamma production in CXCR3-/- mice with experimental autoimmune encephalomyelitis

J Immunol. 2006 Apr 1;176(7):4399-409. doi: 10.4049/jimmunol.176.7.4399.

Abstract

Experimental autoimmune encephalomyelitis (EAE) is a CD4(+) Th1 T cell-mediated disease of the CNS, used to study certain aspects of multiple sclerosis. CXCR3, the receptor for CXCL10, CXCL9, and CXCL11, is preferentially expressed on activated Th1 T cells and has been proposed to govern the migration of lymphocytes into the inflamed CNS during multiple sclerosis and EAE. Unexpectedly, CXCL10-deficient mice were susceptible to EAE, leaving uncertain what the role of CXCR3 and its ligands might play in this disease model. In this study, we report that CXCR3(-/-) mice exhibit exaggerated severity of EAE compared with wild-type (CXCR3(+/+)) littermate mice. Surprisingly, there were neither quantitative nor qualitative differences in CNS-infiltrating leukocytes between CXCR3(+/+) and CXCR3(-/-) mice with EAE. Despite these equivalent inflammatory infiltrates, CNS tissues from CXCR3(-/-) mice with EAE showed worsened blood-brain barrier disruption and more von Willebrand factor-immunoreactive vessels within inflamed spinal cords, as compared with CXCR3(+/+) mice. Spinal cords of CXCR3(-/-) mice with EAE demonstrated decreased levels of IFN-gamma, associated with reduced inducible NO synthase immunoreactivity, and lymph node T cells from CXCR3(-/-) mice primed with MOG(35-55) secreted less IFN-gamma in Ag-driven recall responses than cells from CXCR3(+/+) animals. CXCR3(-/-) lymph node T cells also showed enhanced Ag-driven proliferation, which was reduced by addition of IFN-gamma. Taken with prior findings, our data show that CXCL10 is the most relevant ligand for CXCR3 in EAE. CXCR3 does not govern leukocyte trafficking in EAE but modulates T cell IFN-gamma production and downstream events that affect disease severity.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies / immunology
  • Blood-Brain Barrier / metabolism
  • Blood-Brain Barrier / pathology
  • Cell Proliferation / drug effects
  • Chemotaxis, Leukocyte*
  • Disease Progression
  • Encephalomyelitis, Autoimmune, Experimental / genetics
  • Encephalomyelitis, Autoimmune, Experimental / metabolism*
  • Encephalomyelitis, Autoimmune, Experimental / pathology*
  • Glycoproteins / pharmacology
  • Interferon-gamma / biosynthesis*
  • Interferon-gamma / genetics
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Myelin Proteolipid Protein / pharmacology
  • Myelin-Oligodendrocyte Glycoprotein
  • Nitric Oxide Synthase Type II / immunology
  • Nitric Oxide Synthase Type II / metabolism
  • Peptide Fragments / pharmacology
  • Permeability
  • Receptors, CXCR3
  • Receptors, Chemokine / deficiency*
  • Receptors, Chemokine / genetics
  • Receptors, Chemokine / immunology
  • Receptors, Chemokine / metabolism*
  • T-Lymphocytes / cytology
  • T-Lymphocytes / drug effects

Substances

  • Antibodies
  • Cxcr3 protein, mouse
  • Glycoproteins
  • Myelin Proteolipid Protein
  • Myelin-Oligodendrocyte Glycoprotein
  • Peptide Fragments
  • Receptors, CXCR3
  • Receptors, Chemokine
  • myelin oligodendrocyte glycoprotein (35-55)
  • myelin proteolipid protein (139-151)
  • Interferon-gamma
  • Nitric Oxide Synthase Type II